title: Persistence of CD30 expression in Hodgkin lymphoma following brentuximab vedotin (SGN-35) treatment failure.
authors.forename: Nitya
authors.initials: N
authors.lastname: Nathwani
authors.forename: Amrita Y
authors.initials: AY
authors.lastname: Krishnan
authors.forename: Qin
authors.initials: Q
authors.lastname: Huang
authors.forename: Young
authors.initials: Y
authors.lastname: Kim
authors.forename: Chatchada
authors.initials: C
authors.lastname: Karanes
authors.forename: Eileen P
authors.initials: EP
authors.lastname: Smith
authors.forename: Stephen J
authors.initials: SJ
authors.lastname: Forman
authors.forename: Eric
authors.initials: E
authors.lastname: Sievers
authors.forename: Sandra H
authors.initials: SH
authors.lastname: Thomas
authors.forename: Robert W
authors.initials: RW
authors.lastname: Chen
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000079963:Brentuximab Vedotin; D005260:Female; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism*; D006801:Humans; D018796:Immunoconjugates / Q000627:therapeutic use*; D017730:Ki-1 Antigen / Q000235:genetics / Q000378:metabolism*; D008297:Male; D017211:Treatment Failure; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents; D018796:Immunoconjugates; D017730:Ki-1 Antigen; D000079963:Brentuximab Vedotin